Roche Rebounds, Lilly Lifts, Sanofi Rolls On: Big Pharma China Roundup
This article was originally published in PharmAsia News
Executive Summary
2015 ended with a corporate report card that delighted some but disappointed others, with sales performances veering wildly between growth of more than 20% to declines of about the same. PharmAsia News has combed through multinationals’ earnings reports to bring you the winners, laggards and most successful strategies.
You may also be interested in...
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.